Post-earnings recap
Reported
Tue, Mar 12, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CorMedix Inc. reported a larger-than-expected loss per share in Q4 2023, which contributed to a 2.84% decline in its stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's financial health and future prospects. As there were no comments from management available, it remains unclear how they plan to address these challenges moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.26 | N/A | -23.81% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.